Why this seasoned money manager sees real upside for this innovative B2B tech startup. on 10/26/2021. Learn More
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
BrainStorm Cell Therapeutics Inc. is developing a platform technology based on autologous mesenchymal stem cells that have been induced to secrete a variety of neurotrophic factors. The company is in a Phase 2 trial in ALS after having seen excellent safety and efficacy in earlier clinical studies.
© 2021 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
